Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.82 |
| ▸ | ALPL | P05186 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Int131 SCHEMBL29404335 | 0.90 | PPARG (1.00) | PPARGCYP3A4 | |
| Int131 SCHEMBL30035369 | 0.90 | PPARG (1.00) | PPARGCYP3A4 | |
| Int131 SCHEMBL634767 | 0.90 | PPARG (1.00) | PPARGCYP3A4 | |
| Int131 SCHEMBL635008 | 0.89 | PPARG (0.98) | PPARGCYP3A4 | |
| SCHEMBL10060331 | 0.89 | PPARG (0.82) | PPARGCYP3A4ALPL | |
| SCHEMBL4468243 | 0.86 | PPARG (0.74) | PPARGCYP3A4ALPL | |
| SCHEMBL22732150 | 0.86 | PPARG (0.79) | PPARGCYP3A4ALPL | |
| SCHEMBL22203939 | 0.86 | PPARG (0.83) | PPARGCYP3A4ALPL | |
| SCHEMBL7996313 | 0.86 | PPARG (0.83) | PPARGCYP3A4ALPL | |
| SCHEMBL24318052 | 0.84 | PPARG (0.75) | PPARGCYP3A4ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10426763-B2 | Pharmaceutical compositions comprising glitazones and NRF2 activators | Kahrs, Bjoern Colin (CH) | 2019-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10426763-B2 | Pharmaceutical compositions comprising glitazones and NRF2 activators | PPARG, PPARA, PPARD | PPARG 1/4885CYP3A4 299/4885ALPL 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.